Baxter Q4 2024 Earnings Report
Key Takeaways
Baxter's Q4 2024 revenue totaled $2.75 billion, up 1% year-over-year, exceeding expectations. Adjusted EPS, including discontinued operations, was $0.77, surpassing prior guidance. Strong sales in Pharmaceuticals and Medical Products & Therapies offset weaker results in Healthcare Systems & Technologies. Net income from continuing operations was negative due to special items, including goodwill impairments and restructuring costs.
Revenue reached $2.75 billion, exceeding prior guidance with 1% YoY growth.
Adjusted EPS of $0.77 outperformed the previous guidance range of $0.77-$0.81.
Pharmaceuticals segment saw high single-digit growth, led by injectables and drug compounding.
Hurricane Helene's impact was lower than anticipated, aiding operational performance.
Baxter Revenue
Baxter EPS
Baxter Revenue by Segment
Baxter Revenue by Geographic Location
Forward Guidance
Baxter expects continued revenue growth in 2025, with sales projected to increase 5-6% on a reported basis. Adjusted EPS is expected to be between $2.45 and $2.55 for FY 2025.
Positive Outlook
- Projected 5-6% revenue growth in FY 2025.
- Strong momentum in Pharmaceuticals and Medical Products & Therapies segments.
- Operational improvements post-Kidney Care divestiture.
- Lower-than-expected Hurricane Helene impact.
- Focus on debt repayment and cash flow improvement.
Challenges Ahead
- Continued challenges in Healthcare Systems & Technologies segment.
- Supply constraints impacting select product lines.
- Competitive pricing pressures in key markets.
- Macroeconomic uncertainty affecting global healthcare demand.
- Potential foreign exchange headwinds in international markets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income